Seattle Genetics is a reputable company that focuses on the development and commercialization of advanced and empowered therapies based on antibodies to help treat cancer. The company is a leader in the industry of antibody-drug conjugates (ADCs). The company utilizes the ADCs technology to harness the targeting power of monoclonal antibodies. With the harnessing of this targeting ability, these monoclonal antibodies will have the capacity to deliver cell-killing agents directly to the targeted cancerous cells.
The intentions of the antibody-drug conjugates are to spare the non-cancerous cells, which are untargeted. Hence, Seattle Genetics aims at reducing much of the toxic effects of the conventional chemotherapy, while still facilitating antitumor activities. The ultimate intention of the organization is to advance a broad product line to cater for the substantial unmet medical needs that are increasingly growing in the today’s world. The company has been successful over the years in inventing various medications to cater for varied medical needs.
The flagship product of Seattle Genetics was Adcetris (Brentuximab vedotin), which is currently available commercially for two indications in fifty countries. Among these countries, include the USA, Japan, Canada and the European Union members. With the approval of Adcetris, it makes Adcetris the leading product in a new category of ADCs. Seattle Genetics is continuing to expand on its clinical missions to ensure they deliver quality products to the market. To facilitate this, Seattle Genetics is conducting an extensive program of clinical development to assess its therapeutic potential.
Headquartered in Bothell, Washington, which is a suburb of Seattle, Clay Siegall cofounded Seattle Genetics in 1998 as the President, CEO, and Chairperson to the Board. Clay, as a scientist, emphasizes on targeted cancer therapies. The foundation that Clay built Seattle Genetics on was based on the passion for helping others in combination with thoroughgoing research and drug development. Dr. Clay has pioneered various achievements for the company. He oversaw the company gains different strategic licenses for the ADCs technology.
Apart from the drug development, Clay has been actively involved in capital-raising activities, where he had the privilege of securing over $1.2 billion through both private and public funding. From 1991 to 1997, Dr. Clay worked with Bristol-Myers Squibb Pharmaceutical Research Institute. He has also collaborated with the National Cancer Institute. From 1988 to 1991, Clay worked with National Institutes of Health.